Prasugrel , 10mMinDMSO , 150322-43-3
Synonym(s):
5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate;Effient;Efient
CAS NO.:150322-43-3
Empirical Formula: C20H20FNO3S
Molecular Weight: 373.44
MDL number: MFCD09954140
EINECS: 801-962-1
Pack Size | Price | Stock | Quantity |
1ml | RMB159.20 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | 120.0 to 124.0 °C |
Boiling point: | 493.5±45.0 °C(Predicted) |
Density | 1.347 |
storage temp. | 2-8°C |
solubility | DMSO: >5mg/mL (warmed at 60 °C) |
pka | 3.65±0.20(Predicted) |
form | powder |
color | white to beige |
InChIKey | DTGLZDAWLRGWQN-UHFFFAOYSA-N |
CAS DataBase Reference | 150322-43-3(CAS DataBase Reference) |
Description and Uses
Prasugrel is a third-generation thienopyridine that has been developed and launched for the prevention of atherothrombotic events in patients with ACS or following PCI. While the second-generation agent clopidogrel was an improvement over the first-generation ticlopidine, which suffered from gastrointestinal adverse effects and the risk of neutropenia with prolonged use, its delayed onset of action and considerable interpatient variability prompted the search for the next-generation thienopyridine. The mechanism of action of these platelet inhibitors involves initial biological activation to a sulfhydryl metabolite that irreversibly binds to the P2γ12 receptor on platelets via disulfide formation, thereby preventing platelet activation and aggregation by the endogenous agonist adenosine diphosphate (ADP). The advantage of prasugrel over its predecessors is its more efficient and consistent absorption and rapid conversion to its active metabolite. Co-administration of thienopyridines with acetylsalicylic acid (aspirin), an inhibitor of the synthesis of the platelet aggregation mediator thromboxane A2, is an effective antiplatelet strategy and joins antagonists of glycoprotein IIb/IIIa, which target the final step in platelet aggregation, in the medical arsenal combating atherothrombotic events.
Inhibits platelet aggregation (platelet ADPP 2Y12 antagonist).
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H302-H315-H319-H335 |
Precautionary statements | P261-P305+P351+P338 |
Safety Statements | 24/25 |
WGK Germany | 3 |
HS Code | 29349990 |
Hazardous Substances Data | 150322-43-3(Hazardous Substances Data) |